Genmab A/S (NASDAQ:GMAB) Stock Rating Reaffirmed by HC Wainwright

Genmab A/S (NASDAQ:GMABGet Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They currently have a $50.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 70.01% from the company’s previous close.

Several other analysts have also commented on the company. Citigroup lowered Genmab A/S from a “neutral” rating to a “sell” rating in a report on Monday, January 22nd. Truist Financial reissued a “buy” rating and set a $50.00 price target (down previously from $54.00) on shares of Genmab A/S in a report on Tuesday, February 20th. DNB Markets raised Genmab A/S from a “sell” rating to a “buy” rating in a report on Wednesday, November 8th. UBS Group raised Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, December 6th. Finally, Deutsche Bank Aktiengesellschaft raised Genmab A/S from a “hold” rating to a “buy” rating in a research note on Friday, November 10th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $48.50.

View Our Latest Research Report on Genmab A/S

Genmab A/S Price Performance

Shares of GMAB opened at $29.41 on Wednesday. Genmab A/S has a one year low of $26.32 and a one year high of $42.99. The firm has a market capitalization of $19.43 billion, a P/E ratio of 30.64, a PEG ratio of 1.34 and a beta of 0.98. The business has a fifty day moving average of $29.23 and a 200 day moving average of $31.87.

Institutional Investors Weigh In On Genmab A/S

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Alliancebernstein L.P. raised its position in Genmab A/S by 21.0% during the second quarter. Alliancebernstein L.P. now owns 8,187,576 shares of the company’s stock valued at $311,210,000 after purchasing an additional 1,420,915 shares during the period. BlackRock Inc. grew its stake in shares of Genmab A/S by 1.6% during the first quarter. BlackRock Inc. now owns 5,494,689 shares of the company’s stock valued at $198,799,000 after buying an additional 86,571 shares during the last quarter. Capital International Investors grew its stake in shares of Genmab A/S by 2.2% during the second quarter. Capital International Investors now owns 4,197,060 shares of the company’s stock valued at $157,180,000 after buying an additional 88,355 shares during the last quarter. Macquarie Group Ltd. grew its stake in shares of Genmab A/S by 11.1% during the first quarter. Macquarie Group Ltd. now owns 3,484,632 shares of the company’s stock valued at $131,580,000 after buying an additional 347,437 shares during the last quarter. Finally, Wellington Management Group LLP grew its stake in shares of Genmab A/S by 5.8% during the first quarter. Wellington Management Group LLP now owns 3,333,824 shares of the company’s stock valued at $120,618,000 after buying an additional 183,578 shares during the last quarter. 6.29% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

(Get Free Report)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Recommended Stories

Analyst Recommendations for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.